MaaT Pharma to Highlight Data from the Early Access Program of MaaT013 to Treat Acute Graft-Versus-Host Disease (aGvHD) at EBMT 2024
Shots:
- The EAP study in patients (n=140) with SR/SD GI-aGvHD showed a GI-ORR of 52% at D28, OS of 54%, 47% & 42% at 6mos., 12mos. & 18mos., respectively, with 28% achieving CR. OS was greater with 68% vs 24% at 12mos. & 58 vs 24% at 18mos. in MaaT013 responders vs non-responders
- Among a subset of patients (n=49) refractory to steroids & ruxolitinib, GI-ORR was 63% at D28 with 49% achieving CR, OS rates were 52%, 49% & 42% at 6mos., 12mos. & 18mos., respectively, & overall ORR was 61% with 43% CR. OS was greater with 76% vs 6% at 12mos. & 64% vs 6% at 18mos. in MaaT013 responders vs non-responders
- To confirm the EAP data, MaaT013 is being assessed in the P-III (ARES) trial among corticosteroid & ruxolitinib-refractory GI-aGvHD patients
Ref: MaaT Pharma | Image: MaaT Pharma
Related News:- MaaT Pharma Receives Positive Opinion from DSMB for MaaT013 in P-III Trial to Treat Graft Versus Host Disease (GvHD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
